Novel IL-12/IL-23 inhibitors
| IL12/IL23 Inhibitors | ||||||
| Name | Study | UC/Crohns | Mechanism of action | Authors | Results | Adverse events |
| Mirikizumab | LUCENT 1 LUCENT II | Phase III/Phase III | antibody against the p19 subunit of interleukin 23 | Sandborn et al, 202228
Sands et al, 202230 | UC→Clinical remission (22.6% vs 4.8%) at Week 12 compared with placebo with sustained remission. | Nasopharyngitis, UC flare, headache, Gastroenteritis, nausea, Cough, anaemia |
| CD→Clinical and endoscopic remission (43.8% vs 10.9%) at Week 12 | ||||||
| Risankizumab | ADVANCE MOTIVATE FORTIFY | Phase III | Human monoclonal antibody targeting the p19 subunit of IL-23 | Ferrante et al, 202130
Bossuyt et al, 2022.31 | CD→ Clinical remission in 54.3% and endoscopic response (>50% decrease in SES-CD score) in 43.9% at Week 12 | Infections (opportunistic,fungal), Deranged LFTs, Fetal defects (fetal cystic hygroma and hydrops fetalis in a single case), Hypersensitivity reactions |
| Results not encouraging in patients with ileal disease only. | ||||||
| Brazikumab | Phase II | Human monoclonal antibody against the p19 subunit of IL23 | Sands et al, 201733 | CD→Clinical response (100 point decrease in CDAI score) in 49.2% vs 26.7% of placebo at Week 8. | Headache, Nasopharyngitis | |
| Guselkumab | GALAXI-I | Phase II | Human monoclonal antibody against the p19 subunit of IL23 | Sandborn et al, 202234 | CD→ 56% clinical remission and 40% endoscopic response at Week 12. | Anaemia, Headache, Nasopharyngitis, Arthralgia, Upper respiratory tract infection, Abdominal pain |
CD, crohn’s disease; CDAI, crohn's disease activity index; LFTs, liver function tests; SES-CD, simple endoscopic score - crohn's disease; UC, ulcerative colitis.